4/7/2008 | SS | Galderma says some 97% of CollaGenex shares tendered in offer
|
3/19/2008 | SS | CollaGenex shareholder dissatisfied by timing of pending Galderma deal
|
3/19/2008 | SS | Merger of Galderma, CollaGenex clears waiting period hurdle
|
2/26/2008 | SS | CollaGenex, Galderma to combine
|
2/26/2008 | SS | Market Commentary: DoJ approves Sierra Health, UnitedHealth; airlines face more opposition; exchanges extend talks
|
4/9/2007 | CV | CollaGenex files $100 million shelf
|
11/17/2006 | PP | Market Commentary: BJ's secures $61.5 million from stock sale; Vivus negotiates $33.6 million direct placement of stock
|
11/16/2006 | PP | Market Commentary: CollaGenex secures $45.5 million from stock sale; Dendreon prices $45 million offering
|
11/16/2006 | BTPP | New Issue: CollaGenex secures $45.5 million from direct placement of stock
|
11/16/2006 | BT | Market Commentary: Elan bonds on tap; Acorda rises on acquisition buzz; Neurochem, CollaGenex, Dendreon sell PIPEs
|
11/9/2006 | BT | CollaGenex kept at outperform, $19 target, by RBC
|
11/9/2006 | BT | Jefferies keeps CollaGenex at buy, boosts target to $17
|
11/8/2006 | BT | CollaGenex third-quarter revenues boosted by $2.2 million in Oracea net sales
|
11/6/2006 | BT | CollaGenex reiterated at buy by Jefferies
|
11/3/2006 | BT | CollaGenex reiterated at outperform by RBC
|
10/16/2006 | BT | CollaGenex kept at outperform by RBC
|
10/11/2006 | BT | CollaGenex expands credit facility to $10 million
|
10/9/2006 | BT | Jefferies: CollaGenex, Forest Labs beat Q3 estimates; Connetics lags behind
|
10/9/2006 | BT | CollaGenex reiterated at outperform
|
10/2/2006 | BT | CollaGenex at outperform by RBC
|
9/25/2006 | BT | CollaGenex kept at outperform by RBC
|
9/11/2006 | BT | RBC reiterates CollaGenex at outperform
|
9/5/2006 | BT | RBC reiterates CollaGenex at outperform
|
9/1/2006 | BT | CollaGenex responds to non-final rejection of Oracea-related patent
|
8/29/2006 | BT | Jefferies updates specialty pharmaceutical market
|
8/28/2006 | BT | CollaGenex reiterated at outperform by RBC
|
8/22/2006 | BT | RBC reiterates CollaGenex at outperform
|
8/14/2006 | BT | CollaGenex reiterated at outperform by RBC
|
8/3/2006 | BT | CollaGenex maintained at buy by Jefferies
|
8/3/2006 | BT | RBC reiterates CollaGenex at outperform
|
8/2/2006 | BT | CollaGenex Pharmaceuticals reports second-quarter net revenues down at $3.8 million
|
7/20/2006 | BT | CollaGenex gets rejected for Oracea patent
|
7/20/2006 | BT | CollaGenex reiterated at buy by Jefferies
|
7/20/2006 | BT | RBC reiterates CollaGenex at outperform
|
6/28/2006 | BT | CollaGenex at buy by Jefferies
|
5/30/2006 | BT | CollaGenex receives FDA approval for Oracea
|
5/30/2006 | BT | CollaGenex at outperform by RBC
|
5/30/2006 | BT | Market Commentary: Cubist new convertible emerges; Vical zooms; Isis climbs; ISTA off despite news; CollaGenex climbs
|
5/17/2006 | BT | RBC rates CollaGenex at outperform
|
5/3/2006 | BT | Jefferies rates CollaGenex at buy
|
3/21/2006 | BT | European Patent Office to allow CollaGenex's Oracea
|
3/13/2006 | BT | Jefferies puts CollaGenex at buy
|
3/3/2006 | BT | CollaGenex signs pact with Cardinal Health to manufacture Oracea
|
3/1/2006 | BT | CollaGenex at buy by Jefferies
|
2/28/2006 | BT | CollaGenex extends marketing pact with QLT, raises royalty payments
|
2/28/2006 | BT | CollaGenex at buy by Jefferies
|
2/27/2006 | BT | CollaGenex files marketing authorization application for Oracea for rosacea
|
2/8/2006 | BTCV | CollaGenex Pharma files $75 million shelf
|
12/22/2005 | PP | Market Commentary: New Dragon wraps $9.5 million convertible preferred deal; gold may make comeback, sellsider says
|
12/21/2005 | PP | Market Commentary: CollaGenex to settle $29 million direct offering; Cambridge Display gets agreements for stock offering
|
12/21/2005 | BTPP | New Issue: CollaGenex receives agreements for $29 million direct placement of stock
|
12/16/2005 | BT | Jefferies initiates CollaGenex at buy
|
12/15/2005 | BT | CollaGenex to acquire SansRosa
|
12/15/2005 | BTPP | CollaGenex Pharmaceuticals extends exchange offer to series D convertible preferreds
|
9/15/2005 | BT | Collagenex Pharmaceuticals files $50 million common stock shelf
|